– USA, MA – MOMA Therapeutics, a biopharmaceutical company discovering a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced the appointment of Jeff Albers to its Board of Directors as independent chair, bringing more than 20 years of biopharmaceutical industry experience in the oncology and rare disease spaces.
“Jeff is a seasoned industry leader who is widely recognized for his strategic thinking, humility and breadth of experience. As we continue to advance MOMA’s vision of drugging highly dynamic targets in a way that benefits humankind, having Jeff as a colleague and partner on the journey is an enormous advantage,” said CEO, Dr. Asit Parikh..
About Jeff Albers
Most recently, he served as CEO of Blueprint Medicines until 2022, where he led the company through an initial public offering and evolved it into a leading precision medicine company. Before that, Mr. Albers was president of Algeta, ahead of the company’s acquisition by Bayer, and held senior commercial and corporate development positions at Genzyme, including VP of the U.S. hematology and oncology business unit.
Mr. Albers is currently the board chairman of Blueprint Medicines and sits on the board of directors of Kymera Therapeutics and Magenta Therapeutics; he is also a venture partner at Atlas Ventures and serves on the board of advisors for Life Sciences Cares.
“I am excited to partner with MOMA during this critical phase of the company’s evolution,” said Jeff Albers. “I believe in their ‘Science with Purpose’ mission and ever-deepening understanding of drugging highly dynamic proteins. These targets will yield important precision medicines for people living with unmet medical needs.”
He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.
About MOMA Therapeutics
MOMA Therapeutics is committed to discovering the next generation of precision medicines by targeting highly dynamic proteins that underlie human disease. Bringing together seminal scientific advancements in biochemistry, biophysics, structural biology, chemistry, and functional genomics, the company is establishing a platform to exploit a key vulnerability inherent to all dynamic proteins: their dependence on well-coordinated, stepwise changes in protein conformation. By focusing this platform on disease-causing targets, MOMA aims to develop high-impact, precision medicines for patients with unmet medical needs. MOMA Therapeutics is a private company launched in 2020 and is financed by world-class biotech investors.
MOMA’s proprietary drug discovery platform is rapidly accelerating discovery across dynamic difficult-to-drug targets. MOMA anticipates nominating two precision oncology development candidates targeting ATPases in 2023, each of which plays a critical role in defined and prevalent cancer sub-types, to submit Investigational New Drug applications to the U.S. Food and Drug Administration in 2024. In addition to these programs, MOMA is also poised to deliver additional candidates across diverse therapeutic areas in the next few years
For more information: https://momatx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.